Skip to main content
Interview with the Innovators
Insights into the Prostate Cancer Imaging Landscape
Dr Steven Rowe shares insights into the prostate cancer imaging landscape and the logistics involved with different radiotracers, with particular emphasis on PYLARIFY® (piflufolastat F 18). Read More ›

Results from the OSPREY Trial in Pre-Prostatectomy Patients
Dr Steven Rowe continues his discussion of PYLARIFY® (piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients. Read More ›

PYLARIFY Imaging in High-Risk Prostate Cancer
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer. Read More ›

Overview of the Molecular Characteristics of PYLARIFY
Dr Steven Rowe details the molecular characteristics of PYLARIFY® (piflufolastat F 18) and the OSPREY and CONDOR pivotal trials, which led to the FDA approval of PYLARIFY®. Read More ›

Practical Applications and Clinical Utility of PYLARIFY® (piflufolastat F 18) Injection: An ¹⁸F-PSMA PET/CT Imaging Agent for Prostate Cancer
A series of interviews was recently conducted with a panel of experts on prostate cancer imaging modalities that included Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, and Neal D. Shore, MD, FACS, CMO, Surgical Oncology/Urology Genesis Care, US; Director, CPI, Carolina Urologic Research Center, Myrtle Beach, SC. Read More ›

The Importance of Accurate Staging in Prostate Cancer
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer. Read More ›

Use of PYLARIFY® in Specific Patient Groups
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent. Read More ›

PSMA PET Imaging in Patients with Oligometastatic Prostate Cancer
Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer. Read More ›

PYLARIFY and Next-Generation Imaging
Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging. Read More ›

PSMA-Targeted Imaging for Prostate Cancer Treatment
Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment. Read More ›

Page 2 of 5